MINITEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINITEC (MINITEC).
Minitac (misoprostol) is a synthetic prostaglandin E1 analog that inhibits gastric acid secretion and stimulates mucus and bicarbonate production in the stomach, protecting the gastric mucosa. It also induces uterine contractions.
| Metabolism | Metabolized primarily by the liver via prostaglandin 15-dehydrogenase and other enzymes; inactive metabolites excreted renally. |
| Excretion | Minitec (teriparatide) is primarily eliminated via hepatic metabolism and renal excretion of metabolites. Approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in bile and feces. |
| Half-life | Terminal elimination half-life is approximately 1 hour after subcutaneous administration, reflecting rapid clearance. Clinical context: Requires daily subcutaneous dosing; short half-life supports intermittent PTH receptor stimulation for anabolic effect. |
| Protein binding | Approximately 70% bound to plasma proteins, predominantly to albumin, with no specific binding proteins identified. |
| Volume of Distribution | Volume of distribution is approximately 0.12 L/kg (about 8 L in a 70 kg adult), indicating distribution primarily into extracellular fluid. Low Vd suggests limited tissue penetration. |
| Bioavailability | Subcutaneous: Bioavailability is about 95%. No intravenous formulation; oral bioavailability is negligible due to rapid gastrointestinal degradation. |
| Onset of Action | Subcutaneous: Onset of calcium mobilization occurs within 30 minutes, with peak serum concentration reached at 30 minutes. Anabolic effects on bone are observed within 1 month of continuous therapy. |
| Duration of Action | Duration of pharmacodynamic effect (e.g., increased serum calcium) is about 4-6 hours after subcutaneous dose. Clinical note: Daily dosing maintains anabolic window; continuous exposure would cause catabolic effects. |
Oral: 10 mg once daily, titrated to blood pressure response; maximum 20 mg once daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-59 mL/min: 5 mg once daily; eGFR <30 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: 5 mg once daily; Child-Pugh B or C: contraindicated. |
| Pediatric use | Not approved for pediatric use; no established dosing. |
| Geriatric use | Initial 5 mg once daily due to increased sensitivity; titrate cautiously. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MINITEC (MINITEC).
| Breastfeeding | Minoxidil is excreted into human breast milk in small amounts (M/P ratio unknown but likely <1). Limited infant exposure is expected, but safety during breastfeeding has not been well established. Caution is advised; use only if clearly needed and monitor infant for signs of hypotension or fluid retention. |
| Teratogenic Risk | MINITEC (minoxidil) is FDA Pregnancy Category C. In first trimester, there is a potential for fetal harm based on animal studies showing reduced fetal survival and skeletal abnormalities; human data are limited. In second and third trimesters, use may cause fetal tachycardia, hypertrichosis, and fluid overload; risk of neonatal hypotension and electrolyte disturbances. Avoid use in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
Misoprostol is contraindicated in pregnancy because it can cause abortion, premature birth, or birth defects. It should not be used by pregnant women to reduce the risk of NSAID-induced ulcers.
| Serious Effects |
Pregnancy (for ulcer prevention), known allergy to prostaglandins, history of severe hypotension, inflammatory bowel disease.
| Precautions | May cause uterine rupture if used for labor induction; avoid in women with previous uterine surgery. Can cause diarrhea, abdominal pain, and severe bleeding if used for abortion. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, weight, and signs of fluid retention (edema, weight gain). Assess fetal growth and heart rate via ultrasound and non-stress tests. Monitor neonatal blood pressure and electrolyte levels after delivery if used near term. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. However, use in women of childbearing potential should be accompanied by adequate contraception due to potential fetal risks. |